Drugs

, Volume 47, Issue 1, pp 51–65 | Cite as

Torsade de Pointes

Mechanisms and Management
  • Carlo Napolitano
  • Silvia G. Priori
  • Peter J. Schwartz
Review Article

Summary

Torsade de pointes is a polymorphic ventricular tachycardia showing a peculiar electrocardiographic pattern characterised by a continuous twisting in QRS axis around an imaginary baseline.

An abnormally prolonged QT interval is actually associated with torsade de pointes and it is constantly observed in the sinus beats preceding the onset of the arrhythmic event. Prolongation of ventricular repolarisation associated with the development of torsade de pointes can be observed in many clinical conditions, commonly referred to as prolonged QT syndromes, which can be divided into two major groups: (a) idiopathic long QT syndrome (LQTS), which include the Jervell-Lange-Nielsen and the Romano-Ward syndromes; and (b) acquired prolonged QT syndromes, which are largely iatrogenic and may follow treatment with antiarrhythmic drugs, tricyclic antidepressants, phenothiazines or macrolide antibiotics, and may be associated with metabolic disturbances (hypokalaemia, hypocalcaemia and hypomagnesaemia).

Clinical studies have provided criteria for the definition and guidelines for the management of torsade de pointes, while the electrophysiological mechanisms responsible for its onset are still unclear. Two pathogenetic hypotheses have been proposed to account for the electrophysiological mechanisms underlying the condition: (a) re-entry due to a dispersion of refractory periods; and (b) triggered activity initiated by either early or delayed after-depolarisations. Both mechanisms are supported by clinical and experimental observations but a conclusive answer is not yet available.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bailie DS, Inoue H, Kaseda S, Ben-David J, Zipes DP. Magnesium suppression of early after depolarizations and ventricular arrhythmias induced by caesium in dogs. Circulation 77: 1395–1402, 1988PubMedCrossRefGoogle Scholar
  2. Bhandari AK, Scheimann M. The long QT syndrome. Modern Concepts in Cardiovascular Disease 54: 45, 1985Google Scholar
  3. Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation 71: 63–71, 1985PubMedCrossRefGoogle Scholar
  4. Bonatti V, Rolli A, Botti G. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. European Heart Journal 4: 168–179, 1983PubMedGoogle Scholar
  5. Brachman J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 68: 846–856, 1983CrossRefGoogle Scholar
  6. Chow MJ, Piergies AA, Bowsher DJ, Murphy JJ, Kushner W, et al. Torsades de Pointes induced by N-acetylprocainamide. Journal of the American College of Cardiology 4: 621–624, 1984PubMedCrossRefGoogle Scholar
  7. Curry P, Fitchett D, Stubbes W, Kirkler D. Ventricular arrhythmias and hypokalemia. Lancet 2: 231–233, 1976PubMedCrossRefGoogle Scholar
  8. Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. British Heart Journal 63: 342–344, 1990PubMedCrossRefGoogle Scholar
  9. Day CP, McComb JM, Matthews J, Campbell RWF. Reduction in QT dispersion by sotalol following myocardial infarction. European Heart Journal 12: 423–427, 1991PubMedGoogle Scholar
  10. Dessertenne F. Un chapitre nouveau d’electrocardiographie: les variations progressives de l’amplitude de l’electrocardiogramme. Actualites Cardiologiques et Angiologique Internationale 15: 241–258, 1966aGoogle Scholar
  11. Dessertenne F. La tachycardia ventriculaire a deux foyers opposes variable. Archives des Maladies du Coeur et des Vaisseaux 59: 263–272, 1966bPubMedGoogle Scholar
  12. Fowler NO, McCall D, Chou T, Holmes JC, Hanenson IB. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. American Journal of Cardiology 37: 223–230, 1976PubMedCrossRefGoogle Scholar
  13. Franz MR. Long term recording of monophasic action potential from human endocardium. American Journal of Cardiology 51: 1629–1635, 1983PubMedCrossRefGoogle Scholar
  14. Franz MR, Burkhoff D, Spurgeon H, Wiesfeldt ML, Lakatta EG. In vitro validation of a new catheter technique for recording monophasic action potentials. European Heart Journal 7: 34–41, 1986PubMedGoogle Scholar
  15. Gavrilescu S, Luca C. Right ventricular monophasic action potentials in patients with long QT syndrome. British Heart Journal 40: 1014–1018, 1978PubMedCrossRefGoogle Scholar
  16. Guelon D, Bedock B, Chartier C, Haberer JP. QT prolongation and recurrent ‘Torsades de Pointes’ during erythromycin lactobionate infusion. American Journal of Cardiology 59: 168–169, 1987CrossRefGoogle Scholar
  17. Habbab MA, El-Sherif N. Drug-induced Torsades de Pointes: role of early afterdepolarizations and dispersion of repolarization. American Journal of Medicine 89: 241–246, 1990PubMedCrossRefGoogle Scholar
  18. Han J, Moe JK. Non uniform recovery of excitability in ventricular muscle. Circulation Research 14: 44–60, 1964PubMedCrossRefGoogle Scholar
  19. Hii JTY, Wyse GD, Gillis AM, Duff HJ, Solyloo MA, et al. Precordial QT interval dispersion as a marker of Torsades de Pointes. Circulation 86: 1376–1382, 1992PubMedCrossRefGoogle Scholar
  20. Inser JM, Sours HE, Paris AL, Ferrans VJ, Roberts WC. Sudden, unexpected death in avid dieters using the liquid-protein-modifiedfast diet. Observations in 17 patients and the role of prolonged QT interval. Circulation 6: 1401–1412, 1979Google Scholar
  21. Jackman WM, Friday KJ, Anderson JL Aliot EA, Clark M, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Progress in Cardiovascular Diseases 31: 115–172, 1988PubMedCrossRefGoogle Scholar
  22. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. American Heart Journal 54: 59–68, 1957PubMedCrossRefGoogle Scholar
  23. Kahn MN, Logan KR, McComb JM, Adgey JAA. Management of recurrent ventricular tachyarrhythmias associated with QT prolongation. American Journal of Cardiology 47: 1301–1308, 1981CrossRefGoogle Scholar
  24. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de Pointes: the long-short initiating sequence and other clinical features. American Journal of Cardiology 2: 806–817, 1983CrossRefGoogle Scholar
  25. Keren A, Tzivoni D, Gavish D, Levi J, Gottlieb S, et al. Etiology, warning, signs and therapy of Torsades de Pointes. A study of 10 patients. Circulation 64: 1167–1174, 1981PubMedCrossRefGoogle Scholar
  26. Kuchar DDL, Thorburn CW, Sammel NL. Late potentials detected after myocardial infarction: natural history and pathogenetic significance. Circulation 74: 1280–1289, 1986PubMedCrossRefGoogle Scholar
  27. Kuck Kh, Kunze KP, Roewer N. Sotalol induced Torsades de Pointes. American Heart Journal 107: 179–180, 1984PubMedCrossRefGoogle Scholar
  28. Kuo CS, Munakata K, Reddy CP, Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on dispersion of action potential duration. Circulation 67: 1356–1367, 1983PubMedCrossRefGoogle Scholar
  29. Lansman JB, Hess P, Tsien RW. Blockade of current through the single calcium channels by Cd++, Mg++, Ca++. Journal of General Physiology 88: 321–347, 1987CrossRefGoogle Scholar
  30. Malfatto G, Rosen MR, Foresti A, Schwartz PJ. Idiopathic long QT syndrome exacerbated by beta adrenergic blockade and responsive to left cardiac sympathetic denervation: implications regarding electrophysiologic substrate and adrenergic modulation. Journal of Cardiovascular Electrophysiology 13: 1304–1310, 1992Google Scholar
  31. Maloney JD, Nissen RG, McColgan BS. Open clinical studies at a referral centre. Chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents. American Heart Journal 100: 1023–1030, 1980PubMedCrossRefGoogle Scholar
  32. Maor N, Weiss D, Lorber A. Torsades de Pointes complicating AV block: report of two cases. International Journal Cardiology 14: 235, 1987CrossRefGoogle Scholar
  33. Mason JW, Hondeghen LM, Katzung BG. Block of inactivated sodium channels depolarization induced automaticity in guinea pig papillary muscle by amiodarone. Circulation Research 55: 277–285, 1984CrossRefGoogle Scholar
  34. McComb JM, Campbell NPS, Clelend J. Recurrent ventricular tachycardia with QT prolongation after initial valve replacement and its association with intravenous administration of erythromycin. American Journal of Cardiology 54: 922–923, 1984PubMedCrossRefGoogle Scholar
  35. Moore MT, Book MH. Sudden death in phenothiazine therapy. A clinicopathologic study of 12 cases. Psychiatric Quarterly 44: 384–402, 1970Google Scholar
  36. Moss AJ, Liu JE, Gotlieb S, Locati EH, Robinson L, et al. Efficacy of permanent pacing in the management of the long QT syndrome. Circulation 82 (Suppl. III): 181, 1990Google Scholar
  37. Moss AJ, Schwartz PJ, Crampton RS, Locati EH, Carleen E, et al. The long QT syndrome: a prospective international study. Circulation 71: 17–21, 1985PubMedCrossRefGoogle Scholar
  38. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati E, et al. The long QT syndrome prospective longitudinal study of 328 families. Circulation 84: 1136–1144, 1991PubMedCrossRefGoogle Scholar
  39. Motoe K, Saku K, Tashiro N, Hiroki T, Arahva K. Torsades de Pointes and atrioventricular block. Clinical Cardiology 11: 9–13, 1988CrossRefGoogle Scholar
  40. Napolitano C, Bonazzi O, Diehl L, Locati EH, Priori SG, et al. Dispersion of ventricular activation in the long QT syndrome. Circulation 86 (Suppl. I): 391, 1992Google Scholar
  41. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with Quinidine and underlying cellular electrophysiologic mechanism. American Journal of Medicine 89: 235–238, 1990PubMedCrossRefGoogle Scholar
  42. Nguyen PT, Sheimann M, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy and QT interval. Circulation 74: 340, 1986PubMedCrossRefGoogle Scholar
  43. Nishamura M, Follner CH, Singer DA. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. Journal of Pharmacology and Experimental Therapeutics 251: 650–659, 1989Google Scholar
  44. Priori SG, Corr PB. Mechanism underlying early and delayed after depolarizations induced by catecholamine in isolated canine ventricular myocytes. American Journal of Physiology 258: H1796–H1805, 1990PubMedGoogle Scholar
  45. Priori SG, Mantica M, Schwartz PJ. Delayed after depolarizations elicited in vivo by left stellate ganglion stimulation. Circulation 78: 178–185, 1988PubMedCrossRefGoogle Scholar
  46. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of repolarization as a marker to predict efficacy of antiadrenergic therapy. Journal of the American College of Cardiology 21: 94A, 1993Google Scholar
  47. Ricioni N, Castiglioni M, Bartolomei C. Dysopiramide-induced QT prolongation and ventricular tachyarrhythmias. American Heart Journal 105: 870–871, 1983CrossRefGoogle Scholar
  48. Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of Quinidine-induced arrhythmias. Journal of the American College of Cardiology 8: 73A, 1986PubMedCrossRefGoogle Scholar
  49. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the Quinidine associated long QT syndrome: implications for patient care. American Heart Journal 111: 1088–1094, 1986PubMedCrossRefGoogle Scholar
  50. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare in eta’ pedriatica. Clinical Pediatrics 45: 656–683, 1963Google Scholar
  51. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanism in a canine model of erythromycin-associated long QT syndrome. Circulation 88: 1832–1844, 1993PubMedCrossRefGoogle Scholar
  52. Schoonmaker FW, Osten RT, Greenfiled JC Jr. Thioridazine (‘Meilern’) induced ventricular tachycardia controlled with an artificial pacemaker. Annals of Internal Medicine 65: 1076–1078, 1966PubMedGoogle Scholar
  53. Schwartz PJ. The idiopathic long QT syndrome: progress and questions. American Heart Journal 109: 399–411, 1985PubMedCrossRefGoogle Scholar
  54. Schwartz PJ, Locati E. The idiopathic long QT syndrome: pathogenetic mechanisms and therapy. European Heart Journal 6 (Suppl. D): 103–114, 1985PubMedCrossRefGoogle Scholar
  55. Schwartz PJ, Bonazzi O, Locati EH, Napolitano C, Sala S. Pathogenesis and therapy of the long QT syndrome. In Hashiba et al. (Eds) QT Prolongation and ventricular arrhythmias. Annals of the New York Academy of Sciences 644: 112–141, 1992PubMedCrossRefGoogle Scholar
  56. Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, et al. Left cardiac sympathetic denervation in the therapy of the congenital long QT syndrome: a worldwide report. Circulation 84: 503–511, 1991PubMedCrossRefGoogle Scholar
  57. Sclarovsky S, Strasberg B, Lewin RF, Agmon J. Polymorphous ventricular tachycardia: clinical features and treatment. American Journal of Cardiology 44: 339–344, 1979CrossRefGoogle Scholar
  58. Shah A, Schwartz H. Mexiletine for treatment of Torsades de Pointes American Heart Journal 107: 589–591, 1984PubMedCrossRefGoogle Scholar
  59. Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, et al. Early after depolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation 84: 1915–1923, 1991PubMedCrossRefGoogle Scholar
  60. Simpson GG, Roe A, Lewontin RC. Quantitative zoology, p. 440, Harcourt, Brace & Jovanovich, New York, 1969Google Scholar
  61. Stern S, Keren A, Tzivoni D. Torsades de pointes: definition, causative factors and therapy. Experience with sixteen patients. Annals of the New York Academy of Sciences 427: 234–240, 1984PubMedCrossRefGoogle Scholar
  62. Stramba-Badiale M, Guffanti S, Porta N, Frediani M, Beria G, et al. QT interval prolongation and cardiac arrest during therapy with spiramycin in a new-born infant. American Heart Journal 126: 740–742, 1993PubMedCrossRefGoogle Scholar
  63. Strasberg B, Sclarovsky S, Erdberg A, Duffy EC, Lam W, et al. Procainamide-induced Polymorphous ventricular tachycardia. American Journal of Cardiology 47: 1309–1314, 1981PubMedCrossRefGoogle Scholar
  64. Surawicz B. Electrophysiologic substrate of Torsades de Pointes: dispersion of repolarization or early after depolarizations?. Journal of the American College of Cardiology 14: 172–84, 1989PubMedCrossRefGoogle Scholar
  65. Tzivoni D, Keren A, Cohen AM, Loebel H, Zahavi I, et al. Magnesium therapy of Torsades de Pointes. American Journal of Cardiology 53: 528–530, 1984PubMedCrossRefGoogle Scholar
  66. Tzivoni D, Keren A, Stern S, Gotlieb S. Disopyramide-induced Torsades de Pointes. Archives of Internal Medicine 141: 946–947, 1981PubMedCrossRefGoogle Scholar
  67. Ward OC. New familial cardiac syndrome in children. Journal of the Irish Medical Association 54: 103–106, 1964PubMedGoogle Scholar
  68. Wit AL, Rosen MR. After depolarizations and triggered activity. In Fozzard (Ed.) The heart and the cardiovascular system, pp. 1449–1489, Raven Press, New York, 1986Google Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Carlo Napolitano
    • 1
    • 2
  • Silvia G. Priori
    • 1
    • 2
  • Peter J. Schwartz
    • 1
    • 2
  1. 1.Istituto di Clinica Medica Generale e Terapia MedicaUniversità di Milano — Pad. SaccoMilanoItaly
  2. 2.Dipartimento di MedicinaUniversità degli Studi di PaviaPaviaItaly

Personalised recommendations